Lakefront Biotherapeutics NV current report, Q1 FY2019

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of January 2019. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated January 8, 2019, which is attached as Exhibit 99.1.

Key Financial Metrics

The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a conduit for the attached press release.

Material Changes

The document does not detail material changes versus prior periods. It references a press release issued on January 8, 2019, but the content of that release is not included in the provided text.

Guidance, Outlook, and Risks

There is no management commentary, guidance, outlook, or discussion of risks and contingencies within the body of this filing. The text confirms that the information in the attached press release is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8.

Investor Verification Checklist

  • Verify the actual content of the press release dated January 8, 2019 (Exhibit 99.1), as the filing text only references it.
  • Confirm the registrant name is Galapagos NV, noting the discrepancy with the metadata label "Lakefront Biotherapeutics NV."
  • Review the referenced Registration Statements (Forms F-3 and S-8) for context on how the press release information impacts outstanding securities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.